Julie M Gastier-Foster

List of Publications by Year
in descending order

114 papers	28,529 citations	50276 46 h-index	27406 106 g-index
114 all docs	114 docs citations	114 times ranked	43697 citing authors

#	Article	IF	Citations
1	Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation. Nature Genetics, 2022, 54, 170-179.	21.4	29
2	An Educational Assessment of Evidence Used for Variant Classification. Journal of Molecular Diagnostics, 2022, 24, 555-565.	2.8	3
3	The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. Journal of the National Cancer Institute, 2021, 113, 27-37.	6.3	17
4	Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia. Blood, 2021, 137, 364-373.	1.4	37
5	Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. Cancer Cell, 2021, 39, 38-53.e7.	16.8	65
6	Association ofGATA3Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. Journal of the National Cancer Institute, 2021, 113, 408-417.	6.3	16
7	Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. Transplantation and Cellular Therapy, 2021, 27, 490.e1-490.e8.	1.2	14
8	Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident. Science, 2021, 372, .	12.6	85
9	Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. Journal of Clinical Oncology, 2021, 39, 1540-1552.	1.6	19
10	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2021, 39, 3229-3241.	1.6	174
11	Abstract 2118: Non-coding germline GATA3 variants alter chromatin topology and contribute to pathogenesis of acute lymphoblastic leukemia. , 2021, , .		0
12	Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia. Journal of Clinical Investigation, 2021, 131, .	8.2	20
13	Genotype-phenotype correlation: Inheritance and variant-type infer pathogenicity in IQSEC2 gene. European Journal of Medical Genetics, 2020, 63, 103735.	1.3	12
14	Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Childrenâ€™s Oncology Group Trial AALL0331. Journal of Clinical Oncology, 2020, 38, 602-612.	1.6	107
15	Transcriptome analysis of desmoplastic small round cell tumors identifies actionable therapeutic targets: a report from the Childrenâ€™s Oncology Group. Scientific Reports, 2020, 10, 12318.	3.3	28
16	Genetic Characterization of Pediatric Sarcomas by Targeted RNA Sequencing. Journal of Molecular Diagnostics, 2020, 22, 1238-1245.	2.8	9
17	Analysis of Ugandan cervical carcinomas identifies human papillomavirus cladeâ€“specific epigenome and transcriptome landscapes. Nature Genetics, 2020, 52, 800-810.	21.4	40
18	Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. Nature Cancer, 2020, 1, 1113-1127.	13.2	32

#	Article	IF	Citations
19	Childrenâ€™s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2020, 38, 3282-3293.	1.6	136
20	Retrospective clinical trial experimentally validates glioblastoma genome-wide pattern of DNA copy-number alterations predictor of survival. APL Bioengineering, 2020, 4, 026106.	6.2	5
21	Association of heterogeneous MYCN amplification with clinical features, biological characteristicsÂand outcomes in neuroblastoma: A report from the Children's Oncology Group. European Journal of Cancer, 2020, 133, 112-119.	2.8	13
22	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. JAMA Oncology, 2020, 6, 724.	7.1	139
23	Variant Interpretation for Dilated Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, e002480.	3.6	70
24	Expanding the spectrum of CEP55â€associated disease to viable phenotypes. American Journal of Medical Genetics, Part A, 2020, 182, 1201-1208.	1.2	8
25	Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Childrenâ€™s Oncology Group Study ANBL0531. Journal of Clinical Oncology, 2019, 37, 3243-3255.	1.6	61
26	Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group. Cancer Genetics, 2019, 238, 62-68.	0.4	32
27	Samovar: Single-Sample Mosaic Single-Nucleotide Variant Calling with Linked Reads. IScience, 2019, 18, 1-10.	4.1	6
28	Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Reports, 2019, 29, 1675-1689.e9.	6.4	103
29	Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Childrenâ€™s Oncology Group. Haematologica, 2019, 104, e517-e520.	3.5	11
30	No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. Pediatric Blood and Cancer, 2019, 66, e27681.	1.5	8
31	Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2019, 37, 780-789.	1.6	48
32	Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Childrenâ€™s Oncology Group. Blood Advances, 2019, 3, 1647-1656.	5.2	17
33	Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL. Cancer Discovery, 2019, 9, 436-451.	9.4	67
34	Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood, 2019, 133, 1313-1324.	1.4	172
35	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nature Genetics, 2019, 51, 296-307.	21.4	384
36	Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. Blood, 2019, 133, 724-729.	1.4	44

#	Article	IF	Citations
37	Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial.. Journal of Clinical Oncology, 2019, 37, 10011-10011.	1.6	25
38	A revised Children's Oncology Group (COG) neuroblastoma risk classification system: Report from the COG biology study ANBL00B1.. Journal of Clinical Oncology, 2019, 37, 10012-10012.	1.6	1
39	The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia. Blood, 2019, 134, 649-649.	1.4	5
40	Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Childrenâ€™s Oncology Group (COG). Leukemia, 2018, 32, 1370-1379.	7.2	40
41	Genome sequencing identifies somatic BRAF duplication c.1794_1796dupTAC;p.Thr599dup in pediatric patient with low-grade ganglioglioma. Journal of Physical Education and Sports Management, 2018, 4, a002618.	1.2	7
42	Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature, 2018, 553, 511-514.	27.8	90
43	The College of American Pathologists Biorepository Accreditation Program: Results from the First 5 Years. Biopreservation and Biobanking, 2018, 16, 16-22.	1.0	23
44	Isolated late testicular relapse of Bâ€cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and responseâ€based testicular radiation: A Children's Oncology Group study. Pediatric Blood and Cancer, 2018, 65, e26928.	1.5	28
45	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Systems, 2018, 6, 271-281.e7.	6.2	605
46	Pericentromeric regions of homozygosity on the X chromosome: Another likely benign population variant. European Journal of Medical Genetics, 2018, 61, 416-420.	1.3	1
47	Response to Biesecker and Harrison. Genetics in Medicine, 2018, 20, 1689-1690.	2.4	7
48	Genomeâ€wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. International Journal of Cancer, 2018, 142, 1594-1601.	5.1	31
49	Reply to B. Zhang et al. Journal of Clinical Oncology, 2018, 36, 1454-1455.	1.6	0
50	Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Childrenâ€™s Oncology Group AREN0533 Study. Journal of Clinical Oncology, 2018, 36, 1564-1570.	1.6	87
51	Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia: Results of Childrenâ€™s Oncology Group Trial AALL0622. Journal of Clinical Oncology, 2018, 36, 2306-2314.	1.6	185
52	TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. Journal of Clinical Oncology, 2018, 36, 591-599.	1.6	121
53	Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Childrenâ€™s Oncology Group AALL0434 Methotrexate Randomization. Journal of Clinical Oncology, 2018, 36, 2926-2934.	1.6	164
54	Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Childrenâ€™s Oncology Group. Blood, 2018, 132, 815-824.	1.4	97

#	Article	IF	Citations
55	COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy.. Journal of Clinical Oncology, 2018, 36, 10500-10500.	1.6	54
56	MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the childrenâ€™s oncology group. Oncotarget, 2018, 9, 6416-6432.	1.8	31
57	Genomic analysis of adult B-ALL identifies potential markers of shorter survival. Leukemia Research, 2017, 56, 44-51.	0.8	12
58	Targetable kinase gene fusions in high-risk B-ALL: a study from the Childrenâ€™s Oncology Group. Blood, 2017, 129, 3352-3361.	1.4	236
59	Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2017, 64, e26645.	1.5	82
60	A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. Nature Genetics, 2017, 49, 1487-1494.	21.4	255
61	Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Cancer, 2017, 123, 4224-4235.	4.1	97
62	Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2017, 35, 2527-2534.	1.6	64
63	Blood collection in cell-stabilizing tubes does not impact germline DNA quality for pediatric patients. PLoS ONE, 2017, 12, e0188835.	2.5	8
64	Outcome of Children with Standardâ€Risk Tâ€Lineage Acute Lymphoblastic Leukemiaâ€”Comparison among Different Treatment Strategies. Pediatric Blood and Cancer, 2016, 63, 255-261.	1.5	17
65	Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Childrenâ€™s Oncology Group Study AALL0232. Journal of Clinical Oncology, 2016, 34, 2380-2388.	1.6	301
66	Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group. Clinical Cancer Research, 2016, 22, 5582-5591.	7.0	82
67	Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11306-11311.	7.1	151
68	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nature Communications, 2016, 7, 13331.	12.8	218
69	Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Lowâ€Risk Clinical Features: A Report From the Children's Oncology Group. Pediatric Blood and Cancer, 2016, 63, 634-639.	1.5	53
70	Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell, 2016, 29, 186-200.	16.8	118
71	Comprehensive Functional Characterization of Germline ETV6 Variants Associated with Inherited Predisposition to Acute Lymphoblastic Leukemia in Children. Blood, 2016, 128, 1085-1085.	1.4	1
72	Burkitt Lymphoma Genome Sequencing Project (BLGSP): Introduction. Blood, 2016, 128, 1760-1760.	1.4	1

#	Article	IF	Citations
73	Outcomes of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Based on Blast Genotype at Diagnosis: A Report from the Children's Oncology Group. Blood, 2016, 128, 451-451.	1.4	4
74	Minimal Residual Disease Assessment of Remission after Induction Therapy Is Superior to Morphologic Assessment for Risk Stratification in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group (COG). Blood, 2016, 128, 758-758.	1.4	1
75	Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Childrenâ€™s Oncology Group (COG) study.. Journal of Clinical Oncology, 2016, 34, 10528-10528.	1.6	3
76	RNA profiling of desmoplastic small round cell tumors (DSRCTs) using next-generation sequencing.. Journal of Clinical Oncology, 2016, 34, 10552-10552.	1.6	0
77	Mutational Landscape, Clonal Evolution Patterns and Role of RAS Mutations in Relapsed Acute Lymphoblastic Leukemia. Blood, 2016, 128, 4068-4068.	1.4	0
78	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood, 2015, 125, 680-686.	1.4	110
79	Prognostic significance of minimal residual disease in high risk B-ALL: a report from Childrenâ€™s Oncology Group study AALL0232. Blood, 2015, 126, 964-971.	1.4	287
80	Safe integration of nelarabine into intensive chemotherapy in newly diagnosed Tâ€cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatric Blood and Cancer, 2015, 62, 1176-1183.	1.5	76
81	IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. Blood, 2015, 125, 3501-3508.	1.4	177
82	A slowly progressive form of limbâ€girdle muscular dystrophy type 2C associated with founder mutation in the SGCG gene in Puerto Rican Hispanics. Molecular Genetics & Genomic Medicine, 2015, 3, 92-98.	1.2	10
83	Recurrent DGCR8, DROSHA, and SIX Homeodomain Mutations in Favorable Histology Wilms Tumors. Cancer Cell, 2015, 27, 286-297.	16.8	244
84	Variability in pathogenicity prediction programs: impact on clinical diagnostics. Molecular Genetics & Genomic Medicine, 2015, 3, 99-110.	1.2	44
85	Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine, 2015, 17, 405-424.	2.4	20,455
86	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics, 2015, 47, 864-871.	21.4	451
87	Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. Nature Communications, 2015, 6, 7553.	12.8	72
88	A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma. Cancer Discovery, 2015, 5, 920-931.	9.4	88
89	Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nature Communications, 2015, 6, 6604.	12.8	281
90	Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. Lancet Oncology, The, 2015, 16, 1659-1666.	10.7	161

#	Article	IF	Citations
91	Clinical Application of Prognostic Gene Expression Signature in Fusion Geneâ€“Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group. Clinical Cancer Research, 2015, 21, 4733-4739.	7.0	21
92	Genomic Analysis of Adult B-ALL Identifies Changes in Copy Number Profile at Relapse and IKZF1/CDKN2A Co-Deletion at Diagnosis As a Marker of Shorter Survival. Blood, 2015, 126, 1427-1427.	1.4	1
93	International Laboratory Comparison of Methodologies for Determining Minimal Residual Disease (MRD) in Childhood Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Blood, 2015, 126, 2612-2612.	1.4	2
94	Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG). Blood, 2015, 126, 807-807.	1.4	5
95	Outcomes of dasatinib plus intensive chemotherapy or stem cell transplant (SCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) on Childrenâ€™s Oncology Group AALL0622.. Journal of Clinical Oncology, 2015, 33, 10006-10006.	1.6	9
96	TCF21 hypermethylation in genetically quiescent clear cell sarcoma of the kidney. Oncotarget, 2015, 6, 15828-15841.	1.8	46
97	Clinical application of prognostic gene expression signature in fusion gene-negative rhabdomyosarcoma: A report from the Childrenâ€™s Oncology Group.. Journal of Clinical Oncology, 2015, 33, 10510-10510.	1.6	0
98	Germline Genetic Variation in ETV6 and Predisposition to Childhood Acute Lymphoblastic Leukemia. Blood, 2015, 126, 695-695.	1.4	2
99	Neurodevelopmental disorders among individuals with duplication of 4p13 to 4p12 containing a GABAA receptor subunit gene cluster. European Journal of Human Genetics, 2014, 22, 105-109.	2.8	20
100	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
101	Atypical breakpoint in a t(6;17) translocation case of acampomelic campomelic dysplasia. European Journal of Medical Genetics, 2014, 57, 315-318.	1.3	6
102	Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol Escherichia coli L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4. Journal of Clinical Oncology, 2014, 32, 3874-3882.	1.6	91
103	Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Childrenâ€™s Oncology Group (COG) Study AALL0331. Blood, 2014, 124, 793-793.	1.4	15
104	The impact of initial cerebrospinal fluid (CSF) findings on outcome among patients with NCI standard (SR) and high-risk (HR) B-lymphoblastic leukemia (ALL): A report from the Childrenâ€™s Oncology Group (COG) Studies AALL0331 and AALL0232.. Journal of Clinical Oncology, 2014, 32, 10016-10016.	1.6	1
105	Preliminary analysis of the mutational landscape of non-rhabdomyosarcoma soft tissue sarcoma: A Children's Oncology Group study.. Journal of Clinical Oncology, 2014, 32, 10510-10510.	1.6	1
106	A Genome-Wide Association Study of Susceptibility to Acute Lymphoblastic Leukemia in Adolescents and Young Adults. Blood, 2014, 124, 132-132.	1.4	1
107	Cryptic Truncating Rearrangements of the Erythropoietin Receptor in Ph-like Acute Lymphoblastic Leukemia. Blood, 2014, 124, 128-128.	1.4	0
108	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nature Genetics, 2013, 45, 1494-1498.	21.4	264

#	Article	IF	Citations
109	Assessment of end induction minimal residual disease (MRD) in childhood B precursor acute lymphoblastic leukemia (ALL) to eliminate the need for day 14 marrow examination: A Childrenâ€™s Oncology Group study.. Journal of Clinical Oncology, 2013, 31, 10001-10001.	1.6	4
110	Relationship of fusion protein status and outcome for children with intermediate-risk rhabdomyosarcoma: A Children's Oncology Group report.. Journal of Clinical Oncology, 2012, 30, 9535-9535.	1.6	3
111	Masked Hypodiploidy: Hypodiploid Acute Lymphoblastic Leukemia (ALL) in Children Mimicking Hyperdiploid ALL: A Report From the Children's Oncology Group (COG) AALL03B1 Study.. Blood, 2009, 114, 1580-1580.	1.4	7
112	Children with NCI Standard Risk Acute Lymphoblastic Leukemia (ALL) and TEL-AML1 or Favorable Chromosome Trisomies Are Almost Certain to Be Cured with Graduated Intensity Therapy: Results of the CCG - 1991 Study.. Blood, 2009, 114, 320-320.	1.4	1
113	A multicenter study of the frequency and distribution of GJB2 and GJB6 mutations in a large North American cohort. Genetics in Medicine, 2007, 9, 413-426.	2.4	134
114	Two Distinct Subsets of dic(9;12)(p12;p11.2) among Children with B-Cell Precursor Acute Lymphoblastic Leukemia (ALL): PAX5-ETV6 and ETV6-RUNX1 Rearrangements: A Report from the Childrenâ€™s Oncology Group.. Blood, 2007, 110, 1439-1439.	1.4	12